Results 131 to 140 of about 6,459 (257)

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies

Endocrinology, Diabetes & Metabolism
Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as an efficacious treatment for type 2 diabetes mellitus (T2DM) and have demonstrated substantial weight loss effects.
Jimmy Wen, Burhaan Syed, Denise Nadora, Christiane How‐Volkman, Ethan Bernstein, Alina Truong, Muzammil Akhtar, Adam Razick, Jose Puglisi, Eldo Frezza   +9 more
doaj   +1 more source

Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. Materials and Methods This retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m2) initiated on tirzepatide against 50 age‐, sex‐ and BMI‐matched ...
Simon A. Berry, Iona R. Goodman, Eleanor McNally, Jackie Elliott, Ahmed Iqbal   +4 more
wiley   +1 more source

The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon‐Like Peptide‐1‐Based Therapies

Diabetes, Obesity and Metabolism, EarlyView.
Rune Viig Overgaard, Henrik Agersø, Christian Hollensen, Naveen Rathor, Eric M. Bomberg   +4 more
wiley   +1 more source

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐TZP study data

Journal of Diabetes Investigation, EarlyView.
Tirzepatide achieved significant HbA1c reduction in Japanese patients with type 2 diabetes without obesity, regardless of baseline BMI. Weight reduction was BMI‐dependent and enhanced by dietary consultations. No patient developed underweight status during the 6‐month observation period.
Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto, on behalf of the Hokkaido‐TZP Study Group   +10 more
wiley   +1 more source

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity. [PDF]

Diabetes Obes Metab
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Ciudin A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, Hempfling M, Clark LJ, Fan L, Sapin H.   +7 more
europepmc   +2 more sources

The Pharyngeal Resistance Index—A Promising Diagnostic Tool in OSA

Journal of Sleep Research, EarlyView.
ABSTRACT This study investigates the newly developed pharyngeal resistance index derived from computational fluid dynamics analysis of the upper airway in patients with obstructive sleep apnea. The aim was to evaluate this index as a diagnostic and severity assessment tool by comparing it with the apnea‐hypopnea index before and after maxillomandibular
Nils Lucca Kern, Alexander Pugachev, Tobias Ebker, Tim Lukas Elter, Jan Oliver Voß, Axel Bumann, Max Heiland, Simon Bigus   +7 more
wiley   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, Angela T. H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, Hayun Choi, Roger S. McIntyre   +9 more
wiley   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells. [PDF]

Circulation
Ren L, Belbachir N, Zhang H, Thai PN, Huang R, Zhu W, Wu X, Xie M, Gao J, Kim HY, Liu T, Sun J, Ghazizadeh Z, Navedo MF, Wu JC.   +14 more
europepmc   +1 more source